OTCPK:TRVN - Post by User
Post by
GolongGekkoon Feb 17, 2017 6:02pm
73 Views
Post# 25863816
CNBC on Oliceridine - FYI
CNBC on Oliceridine - FYI Oliceridine: A breakthrough therapy for hospital patients
Oliceridine, a new intravenous opioid, is in the final stages of human trials conducted by Trevena.
Studies have shown oliceridine relieves pain like morphine but doesn't cause respiratory depression or constipation, and patients are less likely to build up a tolerance to it.
"Conventional opioid drugs are probably the best analgesics we have, but they have these really serious problems," said Trevena CEO Maxine Gowen. "For too long I think we have been satisfied with them, but I hope compounds like oliceridine provide a much better option."
Source: Trevena
Pennsylvania-based pharmaceutical company Trevena's oliceridine has been given preferential regulatory treatment by the FDA.
In February the FDA gave oliceridine breakthrough therapy designation, which is granted to new therapies intended to treat serious conditions or drugs that demonstrate substantial clinical improvement over available therapies. The special status allows Trevena to communicate more easily with the regulatory agency and allows it to apply for a fast-track review of its new drug application, which the company expects to file in the second half of 2017.
The drawbacks of the drug are that it is no less addictive than morphine and it can only be used in hospital settings. While Trevena is developing an oral form that could have wider use, it is waiting for a partner company to further that project.
What gives Trevena a potential edge is the reduced risk of overdose with oliceridine, said Ritu Baral, senior biotechnology analyst and managing director at Cowen and Company.
"The biggest thing that hospitals get sued for is respiratory depression," Baral said. "Data suggests this drug could be meaningfully safer than morphine."
Best GG